Treatment adherence in concurrent chemoradiation in patients with locally advanced non-small cell lung carcinoma: results of daily intravenous prehydration.

[1]  J. Aerts,et al.  Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Rajeev Gupta,et al.  Concurrent chemoradiation versus radiotherapy alone in cervical carcinoma: A randomized phase III trial , 2013, Asia-Pacific journal of clinical oncology.

[3]  P. Baas,et al.  Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin. , 2013, Clinical lung cancer.

[4]  J. Sonke,et al.  Severe late esophagus toxicity in NSCLC patients treated with IMRT and concurrent chemotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  J. Sonke,et al.  Prognostic parameters for acute esophagus toxicity in intensity modulated radiotherapy and concurrent chemotherapy for locally advanced non-small cell lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Jan-Jakob Sonke,et al.  Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Jan-Jakob Sonke,et al.  Acute esophagus toxicity in lung cancer patients after intensity modulated radiation therapy and concurrent chemotherapy. , 2012, International journal of radiation oncology, biology, physics.

[8]  J. Aerts,et al.  A randomized, multicenter phase II study investigating additional weekly cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: Reporting on the efficacy. , 2012 .

[9]  R. Lieb,et al.  Population-Based Study , 2012 .

[10]  J. Lafitte,et al.  Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations , 2011, European Respiratory Journal.

[11]  P. Baas,et al.  Chemoradiation therapy in nonsmall cell lung cancer , 2011, Current opinion in oncology.

[12]  M. Verheij,et al.  Cetuximab in combination with single agent daily cisplatin chemotherapy concurrent with radiotherapy in locally advanced nonsmall cell lung carcinoma: A feasibility study , 2011 .

[13]  Jose Belderbos,et al.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Sonke,et al.  State-of-the-art lung cancer radiation therapy , 2009, Expert review of anticancer therapy.

[15]  P. Lambin,et al.  Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Sormani,et al.  Short Hydration Regimen and Nephrotoxicity of Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient Treatment in Lung Cancer and Mesothelioma , 2007, Tumori.

[17]  Jan-Jakob Sonke,et al.  Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients. , 2006, International journal of radiation oncology, biology, physics.

[18]  Jose Belderbos,et al.  Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  J. Marko,et al.  How do site-specific DNA-binding proteins find their targets? , 2004, Nucleic acids research.

[20]  L. Boersma,et al.  First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  H. Bartelink,et al.  DNA‐adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy , 2000, International journal of cancer.

[22]  H. Bartelink,et al.  Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European Organization for Research and Treatment of Cancer. , 2000, European journal of cancer.

[23]  H. Fukuda,et al.  European Organization for Research and Treatment of Cancer (EORTC) and International Society for Cutaneous Lymphoma (ISCL) consensus recommendations for the management of cutaneous B-cell lymphomas Blood 2008; 112(5):1600-9 , 2022 .

[24]  J. Verweij,et al.  Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. , 1996, British Journal of Cancer.

[25]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.

[26]  H. Bartelink,et al.  Combined Treatment with Radiation and Anti-Cancer Drugs: Experimental and Clinical Results , 1988 .

[27]  H. Bartelink,et al.  Radiotherapy and cis-diammine dichloroplatinum (II) as a combined treatment modality for inoperable non-small cell lung cancer: a dose finding study. , 1986, International journal of radiation oncology, biology, physics.

[28]  B. Rosenberg.  Noble metal complexes in cancer chemotherapy. , 1977, Advances in experimental medicine and biology.